High serum AREG and/or TGFα levels have been shown to be a predictor of poor response to gefitinib in NSCLC patients with no association between EGFR mutation status and serum AREG and TGFα levels [21]. This evidence concerns the gene TGFA and non-small cell lung carcinoma.